New book by Larry Connors Click here Improve your trading - See how
Featured speakers will include A. Eugene Washington, M.D., M.Sc., executive vice chancellor and provost of University of California, San Francisco, David L. Gollaher, Ph.D., president and chief executive officer, CHI; Sharon Levine, M.D., associate executive medical director, The Permanente Medical Group, Michael Goldberg, partner, Mohr Davidow Ventures, Alan M. Garber, M.D., Ph.D., director, center for health policy and center for primary care and outcomes research, Stanford University, futurist Ian Morrison, Hans Bishop, president, specialty medicine, Bayer HealthCare LLC, Robert B. Hance, president, Abbott Vascular, Carl W. Hull, president and CEO, Gen-Probe Incorporated, Michael A. Mussallem, chairman and CEO, Edwards Lifesciences, John C. Martin, Ph.D., chairman of the board and CEO, Gilead Sciences and Mark D. Smith, M.D., M.B.A., president and CEO, California HealthCare Foundation. Legislators, including Assemblymembers Nathan Fletcher and Jose Solorio, will also speak at the event.
"This forum brings together industry leaders and policy makers for a conversation about the relationship between public policy and biomedical innovation," said Gollaher. "CHI believes that the implications of healthcare reform for life sciences innovation are profound, and health reform proposals must address cost-savings, improve quality and expand coverage without harming future medical breakthroughs."
A topic of discussion at the forum will be the value of biomedical innovation as the cost of medicines and new technologies present challenges to both public and private payers. The biomedical community is opening a dialogue with state and federal policy makers as well as payers and patients on reining in the cost of medicine and medical technology while protecting innovation and encouraging future investment in research and discovery.
The half-day forum will begin with a networking luncheon at 11:30 a.m., followed by the "Healthcare Reform and Assessing the Value of Medical Innovation" discussion at 12:30 p.m., which will include Gollaher, Goldberg, Garber, Levine, and Washington, with Morrison moderating this conversation about competing priorities within current healthcare reform proposals. Assemblymember Nathan Fletcher will then address the attendees on California's role in the healthcare debate. Following his address, top biomedical industry executives in the state of California, including Bishop, Hance and Hull, will discuss how proposed healthcare policies will affect investment and product development. Next, attendees will meet Assemblymember Jose Solorio during a salon interactive session to discuss how industry leaders can effectively engage in the political process. The forum will conclude with "Innovation at the Crossroads: Cardiovascular Medicine and Infectious Disease," featuring Mussallem, Martin and Smith, discussing the latest research from their companies and how federal policy influences product decisions.
CHI has extended the registration deadline due to high demand. The rate for CHI members is $295; non-members is $445 and academic and nonprofits is $95. Visit www.chi.org/hcpf/default.aspx or call 858-551-6677 to register. Members of the media may register at no cost. Visit the forum Web site for details.
About CHI
CHI represents more than 250 leading biotechnology, medical device, diagnostics, and pharmaceutical companies, and public and private academic biomedical research organizations. CHI's mission is to advance responsible public policies that foster medical innovation and promote scientific discovery. CHI's Web site is www.chi.org.
SOURCE: California Healthcare Institute
California Healthcare Institute Nicole Beckstrand 858-551-6677 Beckstrand@chi.org
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302
© Copyright 2009 The Connors Group, Inc.
